4:46 PM
 | 
Nov 14, 2012
 |  BC Extra  |  Company News

Panel backs GSK's Q-Pan H5N1 vaccine

FDA's Vaccines and Related Biological Products Advisory Committee voted 14-0 that safety and immunogenicity data support accelerated approval of Q-Pan H5N1 adjuvanted vaccine from GlaxoSmithKline plc (LSE:GSK: NYSE:GSK) to prevent disease in adults who are at an increased risk of exposure to the influenza A virus subtype H5N1. The panel was divided on the non-voting topic of the options...

Read the full 284 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$35 USD
More Info >